机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China神经外科普外科苏州大学附属第二医院[3]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[4]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[5]Department of Ophthalmology, School of Medicine, Shandong University, Jinan, China[6]Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China[7]Chinese Glioma Cooperative Group (CGCG), Beijing, China[8]China National Clinical Research Center for Neurological Diseases, Beijing, China
Anaplastic glioma is Grade III and the median overall survival is about 37.6 months. However, there are still other factors that affect the prognosis for anaplastic glioma patients due to variable overall survival. So we screened four-lncRNA signature (AGAP2-AS1, TPT1-AS1, LINC01198 and MIR155HG) from the lncRNA expression profile from the GSE16011, CGGA and REMBRANDT datasets. The patients in low risk group had longer overall survival than high risk group (median OS 2208.25 vs. 591.30 days; P < 0.0001). Moreover, patients in the low risk group showed similar overall survival to Grade II patients (P = 0.1669), while the high risk group showed significant different to Grade IV (P = 0.0005) with similar trend. So based on the four-lncRNA, the anaplastic gliomas could be divided into grade II-like and grade IV-like groups. On the multivariate analysis, it showed the signature was an independent prognostic factor (P = 0.000). The expression of four lncRNAs in different grades showed that AGAP2-AS1, LINC01198 and MIR155HG were increased with tumor grade, while TPT1-AS1 was decreased. Knockdown of AGAP2-AS1 can inhibit the cell proliferation, migration and invasion, while increase the apoptosis cell rates in vitro. In conclusion, our results showed that the four-lncRNA signature has prognostic value for anaplastic glioma. Moreover, clinicians should conduct corresponding therapies to achieve best treatment with less side effects for two groups patients.
基金：
This work was supported by grants from Ministry of Science and Technology of China grant (2012CB825505 and 2011BAI08B08), National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BAI09B03, 2014BAI04B02), National High Technology Research and Development Program (No.2012AA02A508), National Natural Science Foundation of China (No. 91229121), Beijing Science and Technology Plan (No. Z131100006113018).
第一作者机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China[3]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[7]Chinese Glioma Cooperative Group (CGCG), Beijing, China
通讯作者：
通讯机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China[8]China National Clinical Research Center for Neurological Diseases, Beijing, China
推荐引用方式(GB/T 7714)：
Wen Wang,Fan Yang,Lu Zhang,et al.LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas[J].ONCOTARGET.2016,7(47):77225-77236.doi:10.18632/oncotarget.12624.
APA：
Wen Wang,Fan Yang,Lu Zhang,Jing Chen,Zheng Zhao...&Jizong Zhao.(2016).LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas.ONCOTARGET,7,(47)
MLA：
Wen Wang,et al."LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas".ONCOTARGET 7..47(2016):77225-77236
医学